Prognostic model for unresectable hepatocellular carcinoma treated with transarterial therapy plus TKIs and anti-PD-1 antibodies
The HLNS score provides a useful tool for personalized prognostication and risk classification of uHCC patients treated with transarterial therapy plus TKIs and anti-PD-1 antibodies.
Authors
- Guang Tan (ORCID: https://orcid.org/0000-0002-3571-3698)
- Xing Lv (ORCID: https://orcid.org/0000-0003-3125-6853)
- Tong Yuan (ORCID: https://orcid.org/0000-0003-3211-1322)
- Jun-Jie Liu (ORCID: https://orcid.org/0000-0002-7610-1399)
- Xue Lin (ORCID: https://orcid.org/0000-0001-7934-5682)
- Chunyu Zhang (ORCID: https://orcid.org/0000-0003-0448-1756)
- Pengbo Zhang (ORCID: https://orcid.org/0000-0002-1623-7964)
- Yi Zhou (ORCID: https://orcid.org/0000-0001-9161-6385)
- Ronghua Zhu (ORCID: https://orcid.org/0000-0001-9715-1793)
- Zhiyong Huang (ORCID: https://orcid.org/0009-0003-9855-6073)
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1186/s12957-025-04154-w
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00